NuVasive, Precision Spine, ArthroCare & more — 7 key notes

Here are seven key notes on spine and orthopedic device companies.

Advertisement

Cerapedics filed a premarket approval application with the U.S. Food & Drug Administration for it’s i-FACTOR Peptide Enhanced Bone Graft.

 

NuVasive COO Keith Valentine sold 2,500 shares of the company’s stock on the open market last Tuesday.

 

Precision Spine entered into a development agreement with Stephen D. Cook, PhD, to design a cervical spine disc replacement device.

 

Integra LifeScience made changes to the orthopedics and tissue technology business leadership and structure.

 

Aesculap Biologics announced the first human implantation of the NOVOCART 3D was performed in August by Kenneth R. Zaslav, MD, an orthopedic surgeon with Advanced Orthopedics in Richmond, Va.

 

Prison terms were given to two former ArthroCare executives for a fraud scheme that eventually cost shareholders $750 million.

 

Iconacy Orthopedic Implants formed a strategic alliance with Orthopedic Lean Consulting.

More articles on devices:

Cerapedics applies for FDA premarket approval for peptide enhanced bone graft
NuVasive COO sells 2.5k shares in $87k transaction: 5 things to know
Precision Spine partnership to develop new artificial disc

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new product launches and leadership appointments, here are seven key headlines from Stryker in the first quarter of 2026.…

  • Xtant Medical’s 2025 revenue reached $133.9 million, a 14% increase year over year, according to financial results posted March 31.…

Advertisement

Comments are closed.